Insider Sales: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells 17,500 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Your Free Report ) COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total transaction of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. The transaction was disclosed in a filing with the SEC, which is accessible via this hyperlink.

Eben Tessari also recently made the following transactions:

• On Tuesday, August 27th, Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00.

Price performance of Kiniksa Pharmaceuticals

NASDAQ KNSA traded down $0.35 during trading hours on Wednesday, reaching $24.10. 380,903 shares of the company traded hands, compared to its average volume of 426,539. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $14.12 and a 52-week high of $27.92. The firm has a market cap of $1.72 billion, a PE ratio of 222.29 and a beta of 0.33. The firm has a 50-day simple moving average of $25.30 and a 200-day simple moving average of $21.30.

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report ) last issued its earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The business had revenue of $108.30 million during the quarter, compared to analysts’ expectations of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The company’s revenue for the quarter was up 51.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.02) earnings per share. sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.29 EPS for the current fiscal year.

Institutional inputs and outputs

Several large investors have recently bought and sold shares of KNSA. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the first quarter worth about $71,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the second quarter valued at $100,000. China Universal Asset Management Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 88.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after purchasing an additional 3,611 shares during the last quarter. Lynx1 Capital Management LP purchased a new stake in Kiniksa Pharmaceuticals during the second quarter valued at $177,000. Finally, Arizona State Retirement System bought a new position in Kiniksa Pharmaceuticals in the second quarter valued at $209,000. 53.95% of the shares are held by hedge funds and other institutional investors.

Analyst upgrades and downgrades

A number of equities research analysts have issued reports on the stock. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Jefferies Financial Group assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Five research analysts have rated the stock with a buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $33.60.

Get the latest analysis on Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Company Profile

(Get a free report)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on the discovery, acquisition, development and commercialization of therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that has completed phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40-CD154 interaction, a T-cell costimulatory signal critical for B-cell maturation, immunoglobulin class switching, and the type 1 immune response.

Recommended articles

Get daily news and reviews for Kiniksa Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.